文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

寡进展转移性去势抵抗性前列腺癌立体定向体部放疗后至下次系统治疗时间

Time to Next Systemic Therapy After Stereotactic Body Radiation Therapy for Oligoprogressive Metastatic Castrate-Resistant Prostate Cancer.
PubMed 文献 · Adv Radiat Oncol · 2024-10-20

该单中心回顾性研究纳入2011至2022年接受SBRT的32例寡进展mCRPC患者(共38处转移灶),中位至下次系统治疗时间(TTNST)为10.1个月,中位OS为41.3个月;有无未治疗非进展转移灶两组TTNST为11.3个月 vs 8.7个月(HR 0.67,95%CI 0.33-1.36,P=0.24),无≥3级毒性。作者认为SBRT可能延迟精选患者(包括有≥1处未治疗非进展转移灶者)的下一线系统治疗。

要点

  • 32例寡进展mCRPC患者接受SBRT后中位TTNST为10.1个月。
  • 有无未治疗非进展转移灶的TTNST为11.3 vs 8.7个月(HR 0.67,95%CI 0.33-1.36,P=0.24)。
  • SBRT后中位OS为41.3个月,未观察到≥3级毒性。

核心结论

  • 在本队列中,接受SBRT的寡进展mCRPC患者将下一线系统治疗延迟了中位10.1个月。
  • 作者认为SBRT可能延迟精选患者(包括有≥1处未治疗非进展转移灶者)的下一线系统治疗。

研究设计与样本

  • 单中心回顾性研究,纳入2011年至2022年接受SBRT的32例寡进展mCRPC患者,共38处转移灶。
  • 主要终点为按有无未治疗非进展转移灶分层的SBRT后至下次系统治疗时间(TTNST)。
  • 次要终点包括总体队列的TTNST和SBRT后中位总生存期(OS)。

主要发现

  • 患者SBRT时中位年龄72.5岁(范围50.6-84.3),中位PSA 6.85 ng/mL(范围0.39-922.0)。
  • 最常用SBRT方案为3000 cGy分5次(18处转移灶,47.4%)。
  • 16例患者接受所有已知病灶SBRT,16例患者接受寡进展转移灶SBRT但SBRT时至少有1处未治疗非进展转移灶。
  • 患者接受中位1.0线既往雄激素受体信号抑制剂治疗,以未接受化疗为主(26例,81.3%)。
  • SBRT后中位TTNST为10.1个月,中位OS为41.3个月;0处 vs ≥1处未治疗非进展转移灶患者TTNST为11.3个月 vs 8.7个月(HR 0.67,95%CI 0.33-1.36,logrank P=0.24)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with metastatic castrate-resistant prostate cancer (CRPC) with progressive disease generally require a change or escalation in systemic therapy. For patients with limited (1-3) sites of progressive disease (oligoprogression), metastasis-directed therapy with stereotactic body radiation therapy (SBRT) may allow a longer interval before next-line systemic therapy. METHODS AND MATERIALS: This is a retrospective study of patients with oligoprogressive metastatic CRPC (mCRPC) treated with SBRT at a single center between 2011 and 2022. The primary endpoint was time to next systemic therapy (TTNST) after SBRT stratified by the presence/absence of untreated nonprogressing metastases. Secondary endpoints included TTNST of the overall cohort and median overall survival (OS) after SBRT. RESULTS: Thirty-two patients with oligoprogressive mCRPC received SBRT to 38 metastases. Patients had a median age of 72.5 years (range, 50.6-84.3) and a median PSA of 6.85 ng/mL (range, 0.39-922.0) at the time of SBRT. The most commonly used SBRT regimen was 3000 cGy in 5 fractions (18 metastases, 47.4%). Sixteen patients were treated to all known sites of disease, whereas 16 patients received SBRT to oligoprogressive metastases but had at least 1 untreated nonprogressing metastasis at the time of SBRT. Patients had received a median of 1.0 prior line of androgen receptor signaling inhibitors and were predominantly (26 patients, 81.3%) chemotherapy naïve. Following SBRT, the median TTNST was 10.1 months and the median OS was 41.3 months. For patients with 0 versus ≥1 untreated nonprogressing metastasis, TTNST was 11.3 versus 8.7 months, respectively (HR, 0.67; 95% CI, 0.33-1.36, logrank P = .24). There was no grade ≥3 toxicities because of SBRT. CONCLUSIONS: In this cohort, patients with oligoprogressive mCRPC treated with SBRT delayed the next line of systemic therapy for a median of 10.1 months. SBRT in patients with oligoprogressive mCRPC may delay initiation of the next-line systemic therapy in well-selected patients, including those with ≥1 untreated nonprogressing metastasis.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Eule CJ, Candelario N, Nath SK, et al. Time to Next Systemic Therapy After Stereotactic Body Radiation Therapy for Oligoprogressive Metastatic Castrate-Resistant Prostate Cancer. Adv Radiat Oncol. 2024. PMID: 39620140. doi:10.1016/j.adro.2024.101655

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。